Senior Director, Mavacamten Medical Product Lead

At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits. This is work that transforms the lives of patients, and the careers of those who do it. This position plays a critical role in the development and execution of BMS' WW & US medical strategy within our Mavacamten (Camzyos®) cardiovascular portfolio. The Global Medical Mavacamten Medical Product Lead (MPL) is a strategic leader with a broad scope of responsibilities within the Worldwide Medical organization and a key leader of the cross-functional matrix, providing medical insights and interpretation of the evolving cardiomyopathy landscape and disseminating clinical data across the organization. The MPL has overall accountability to develop aligned medical strategies and execute core medical deliverables, including Integrated Evidence Plans, Scientific Narratives, and External Engagement and Advocacy plans as the lead of the cross-functional Asset/Indication Medical Strategy (AIMS) team. The Senior Director, MPL will have oversight over the Mavacamten asset across the full spectrum of hypertrophic cardiomyopathy (HCM) indications — both obstructive (oHCM) and non-obstructive (nHCM) — and related life cycle management opportunities, and should be able to direct and navigate complex issues across the broad cross-functional matrixed partners to ensure optimal medical affairs strategy is developed and executed. Develop and execute the WW & US Medical Affairs strategy for Mavacamten (Camzyos®) across all HCM indications, including obstructive and non-obstructive HCM, ensuring alignment with the overall BMS cardiovascular disease area strategy. Act as the core global medical representative for WW & US Mavacamten Program Teams, providing strategic medical and scientific leadership across all cross-functional forums. Lead the cross-functional Asset/Indication Medical Strategy (AIMS) team for Mavacamten, setting strategic direction and aligning medical deliverables across global markets. Ensure Mavacamten is effectively positioned within the BMS cardiovascular disease area strategy, integrating competitive intelligence and an evolving understanding of the cardiomyopathy landscape. Participate in the Cardiovascular Leadership Team (LT) to drive business priorities and represent the medical affairs perspective at the highest organizational levels. Oversee and guide asset development strategy across the full Mavacamten life cycle, including new indications, label expansions, and post-marketing evidence generation in HCM and related cardiomyopathies. Develop and execute WW & US medical strategy, scientific narratives, and provide medical insights to inform the global medical plan for Mavacamten, with deep expertise in myosin inhibition and cardiac muscle physiology. Lead workstreams to identify evidence gaps and develop comprehensive Integrated Evidence Plans (IEPs), including both interventional and non-interventional research strategies in HCM populations globally. Establish and oversee global medical data generation strategies; collaborate with Medical Evidence Generation (MEG) to oversee the execution of Investigator Sponsored Research (ISR) programs for Mavacamten from concept through full execution, including reporting at scientific congresses, in peer-reviewed publications, and through proactive/reactive BMS communication tools. Deliver WW & US Medical Communications plans for Mavacamten, including global publications strategy, symposia, scientific exchange, and data dissemination at key cardiovascular congresses (e.g., AHA, ACC, ESC, HFSA). Engage with high-impact